Sopan Pharmaceuticals Limited (SOPL)
Manufacturing · Rs. 795.00 -1.00 (-0.13%) as of Aug 17, 2026
Price — last 6 months
Full chart →Open
790.00
High / Low
800.80 / 790.00
Prev. close
796.00
Volume
30,604
52-week high
—
52-week low
—
Market cap
—
Shares outstanding
—
MASTER score
Mechanical 0–100 technical ranking. Methodology →
Promoter holding—
Public holding—
Stock performance
1-week change
-0.13%
1-month change
-3.41%
3-month change
—
6-month change
—
YTD change
—
1-year change
—
1-month high
948.00
1-month low
760.00
From 52-week high
—
From 52-week low
—
180-day avg price
802.64
360-day avg price
802.64
Avg volume (1w)
25,570
Avg volume (1m)
42,004
Avg volume (6m)
55,559
Avg volume (12m)
55,559
Daily volatility (1m)
2.29%
Beta vs NEPSE (1y)
—
Valuation
EPS (annualized)
—
EPS (TTM)
—
P/E
—
P/B
—
Book value / share
—
ROE
—
ROA
—
Net profit margin
—
Graham number
—
Dividend yield
—
Dividend
—
P/E and P/B use the latest close over per-share values from the company's most recent filed statement. Full dividend history →
Key indicators vs Manufacturing
EPS (Rs.)
N/A
min -6.83avg 189.33max 658.99
—
P/E
N/A
min 37.84avg 60.55max 112.02
—
P/B
N/A
min 2.02avg 5.23max 9.27
—
Networth / Share (Rs.)
N/A
min 97.50avg 1,391.83max 5,114.98
—
ROE (%)
N/A
min 0.00avg 8.30max 23.35
—
Technical indicators
| RSI (14) | 52.53 | Neutral |
| MACD | -2.94 | Bearish |
| EMA 5 | 799.64 | Bearish |
| EMA 20 | 810.73 | Bearish |
| EMA 180 | — | — |
| SMA 50 | 812.61 | Bearish |
| SMA 200 | — | — |
Pivot levels (classic)
S3
778.93S2
784.47S1
789.73PP
795.27R1
800.53R2
806.07R3
811.33Key financials — last 8 quarters
worsebetter vs same quarter last yearamounts in Rs · per-share in RsNo filed statements found.
More Manufacturing stocks
SOPL — frequently asked questions
What is Sopan Pharmaceuticals Limited's share price?
Rs. 795.00 as of Aug 17, 2026, the latest NEPSE trading session (-0.13% on the day).
What dividend did SOPL pay?
No dividend on record for the most recent fiscal year in our data.
Prices from the latest NEPSE session; fundamentals from the company's published quarterly statements. Research reference only — not investment advice.